Litigation Details for In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)
✉ Email this page to a colleague
In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-07-31 |
| Court | District Court, D. Delaware | Date Terminated | 2024-04-15 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Colm Felix Connolly |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,001,884; 6,011,068; 6,211,244; 6,313,146; 7,829,595; 9,375,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Biologic Drugs cited in In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-09-20 | 16 | Redacted Document | against the patents covering Sensipar. Among these patents were U.S. Patent Nos. 6,011,068 (the ’068 patent…the ’068 patent and certain other patents (collectively, the “NPS Patents”). The NPS Patents relate to…’405 Patent 31. The U.S. Patent and Trademark Office (“PTO”) issued the ’405 patent in 2016… patent”) and 9,375,405 (“the ’405 patent”), which expired on March 8, 2018 and September 22, 2016, respectively…challenge the ’068 patent, all filed “Paragraph IV” certifications against the ’405 patent, stating that | External link to document |
| 2020-07-23 | 160 | Redacted Document | The patent covering the cinacalcet drug substance, U.S. Patent No. 6,011,068 (“ʼ068 patent”), expired….) However, Amgen also owns U.S. Patent No. 9,375,405 (“ʼ405 patent”), which is listed in the Orange …ʼ405 (formulation) patent, i.e., the generic manufacturers asserted that the patent was invalid, unenforceable…claims but would lose if the patent litigation were to continue and the patent were held invalid or not … not involve the assertion of patent rights or the settlement of patent ligation. Actavis, in contrast | External link to document |
| 2019-09-20 | 17 | Redacted Document | covering Sensipar – U.S. Patent Nos. 6,211,244 (expiry October 23, 2015); 6,001,884 (expiry December 14, …068 patent, ’003 patent, ’244 patent,’146 patent, and ’884 patent (collectively, the “NPS Patents”). … Amgen’s drug substance patent – U.S. Patent No. 6,011,068 (“the ’068 Patent”) – expired on March 8, …obtained a new patent purportedly covering Sensipar, U.S. Patent No. 9,375,405 (“the ’405 patent”). This patent…and the ’405 patent (issued June 28, 2016) from those patents’ inventors. The ’405 patent is a formulation | External link to document |
| 2019-10-22 | 57 | Notice of Service | “The NPS Patents” means collectively U.S. Patent Nos. 6,211,244 (the ’244 Patent); 6,001,884 (the ’884…884 Patent); 6,031,003 (the ’003 Patent); 6,313,146 (the ’146 Patent); 6,011,068 (the ’068 Patent); 7,829,595…7,829,595 (the ’595 Patent); and 9,375,405 (the ’405 Patent). G. “Sensipar Patent Litigation” means…any NPS Patents and related conduct in the prosecution of the underlying patent applications…listing of any NPS Patents in the FDA’s Orange Book; c. institution of any patent infringement | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
